FR2963832B1 - Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications - Google Patents

Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications

Info

Publication number
FR2963832B1
FR2963832B1 FR1056601A FR1056601A FR2963832B1 FR 2963832 B1 FR2963832 B1 FR 2963832B1 FR 1056601 A FR1056601 A FR 1056601A FR 1056601 A FR1056601 A FR 1056601A FR 2963832 B1 FR2963832 B1 FR 2963832B1
Authority
FR
France
Prior art keywords
fibrinogen
thrombin
quantifying
generation
applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1056601A
Other languages
English (en)
Other versions
FR2963832A1 (fr
Inventor
Michel Hanss
Bernadette Boisselon
Patrick Ffrench
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospices Civils de Lyon HCL
Original Assignee
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospices Civils de Lyon HCL filed Critical Hospices Civils de Lyon HCL
Priority to FR1056601A priority Critical patent/FR2963832B1/fr
Priority to PCT/FR2011/051883 priority patent/WO2012020196A1/fr
Publication of FR2963832A1 publication Critical patent/FR2963832A1/fr
Application granted granted Critical
Publication of FR2963832B1 publication Critical patent/FR2963832B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR1056601A 2010-08-13 2010-08-13 Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications Active FR2963832B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1056601A FR2963832B1 (fr) 2010-08-13 2010-08-13 Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications
PCT/FR2011/051883 WO2012020196A1 (fr) 2010-08-13 2011-08-08 Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056601A FR2963832B1 (fr) 2010-08-13 2010-08-13 Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications

Publications (2)

Publication Number Publication Date
FR2963832A1 FR2963832A1 (fr) 2012-02-17
FR2963832B1 true FR2963832B1 (fr) 2013-03-15

Family

ID=43466642

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1056601A Active FR2963832B1 (fr) 2010-08-13 2010-08-13 Procede de quantification de l'effet potentialisateur du fibrinogene sur la generation de thrombine et ses applications

Country Status (2)

Country Link
FR (1) FR2963832B1 (fr)
WO (1) WO2012020196A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056190A1 (fr) * 2013-10-16 2015-04-23 Institut National De La Sante Et De La Recherche Medicale Surveillance simultanée des fibrinogènes et des hématocrites dans le sang complet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133946A1 (de) * 1991-10-14 1993-04-15 Behringwerke Ag Funktioneller test und reagenz zur bestimmung von fibrinogen
FR2798469A1 (fr) 1999-09-15 2001-03-16 Michel Marie Luc Hanss Procede de recherche in vitro d'une anomalie du fibrinogene
EP2987498B1 (fr) * 2008-05-02 2017-07-05 Laboratoire Français du Fractionnement et des Biotechnologies Traitement de saignement par un fibrinogène de faible demi-vie

Also Published As

Publication number Publication date
WO2012020196A1 (fr) 2012-02-16
FR2963832A1 (fr) 2012-02-17

Similar Documents

Publication Publication Date Title
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
BRPI1011025A8 (pt) Métodos para o diagnóstico de distúrbios metabólicos usando transferidores epimetabólicos, moléculas intracelulares multdimensionais ou influenciadores ambientais
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
WO2010082944A3 (fr) Systèmes et procédés d'imagerie de changements au niveau de tissus
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
WO2010091049A3 (fr) Diagnostic et traitement du cancer
WO2010068794A3 (fr) Inhibiteurs de hif et leurs applications
BR112012026536A2 (pt) sistemas e métodos para predizer deficiência gastrointestinal
BR112014029301A2 (pt) métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
BR112014026661A2 (pt) método in vitro para diagnóstico e vigilância do câncer
BRPI0821105A2 (pt) ferramentas terapêuticas e de diagnóstico para doenças que alteram a função vascular
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
SG179070A1 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
EA201201482A1 (ru) Селективные ингибиторы интегрина
BR112013021035A2 (pt) composições e métodos de reposição de tecido macio aperfeiçoados
BRPI1002094A2 (pt) Utilização de pelo menos uma forma peptidica solúvel, e processos de triagem de ativos anti-idade e de caracterização da eficácia de um tratamento

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14